SAVA News and Press, Cassava Sciences Inc. From 01/09/24

2024-01-09 02:10:50 ET Summary Cassava's Market Position: Despite a $1 billion valuation, concerns about simufilam, its lone Alzheimer's drug, cast doubt on its prospects. Clinical Development Challenges: Simufilam faces rigorous Phase 3 trials, critical due to its unconvincing pr...

2024-01-05 16:55:03 ET Summary Sigma-1 receptor agonists such as Anavex's blarcamesine, Aricept, and possibly Cassava Sciences's simufilam may slow down the early progression of Alzheimer's disease. Blarcamesine may have an advantage over other sigma-1 receptor agonists due to its...

Shareholders of Record Received Warrants to Purchase Shares of Common Stock Warrants Trade on Nasdaq Under the Ticker “SAVAW” Warrant Holders Who Choose to Exercise During an Early Period Will Receive an Additional 0.5 of a Common Share Per Warrant AUSTIN, ...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

2023-12-21 10:50:37 ET Summary Cassava Sciences stock has increased by 50% since October due to positive safety data for its Alzheimer's disease candidate simufilam. The safety data shows that simufilam does not have a critical safety issue associated with another Alzheimer's drug...

2023-12-21 10:00:01 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector For further details see: Cassava Sciences, Myomo among healthcare movers

2023-12-21 08:16:36 ET Losers: Polished.com ( POL ) -36% . Dune Acquisition Corporation ( DUNE ) -17% . Panbela Therapeutics ( PBLA ) -10% . Applied UV ( AUVI ) -9% . Tantech Holdings Ltd ( TANH ) -9% . Longeveron ( LGVN ...

2023-12-15 18:06:45 ET Thanks to a shareholder-pleasing move, Cassava Sciences (NASDAQ: SAVA) stock was an outperformer in the biotech sector this week. Over the period, the company's shares gained 21% in value, according to data compiled by S&P Global Market Intelligence . ...

2023-12-12 14:02:18 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of pharmaceutical specialist Cassava Sciences (NASDAQ: SAVA ) soared earlier Tuesday before giving up most of the gains. Nevertheless, investor enthusiasm spiked over managem...

2023-12-12 12:15:42 ET More on Cassava Sciences Cassava Sciences - How To Interpret 3 'Positive' Updates Shared In Q3 Cassava Sciences: Likely Potential Opportunity From Phase 3 Readout Next Year Cassava Sciences' Simufilam Does Not Appear To Be Effective Against Alz...